We found no differences between the groups of patients in terms of sex, duration of T2DM, anthropometric characteristics, frequency of dyslipidemia, hypertension, abdominal obesity, CKD, systolic and diastolic blood pressure, LV cavity dimensions, LVEF, LAVI, E/e′, GLS, HOMA-IR score, fasting glucose, HbA1c, creatinine, lipids, hs-CRP, TNA-alpha, or medications (excluding antiplatelet agents/anticoagulants and SGLT2 inhibitors). This evidence concerns the gene SLC5A2 and metabolic syndrome.